BioCardia Statistics
Total Valuation
BioCardia has a market cap or net worth of $15.18 million. The enterprise value is $10.53 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioCardia has 10.61 million shares outstanding. The number of shares has increased by 160.84% in one year.
| Current Share Class | 10.61M |
| Shares Outstanding | 10.61M |
| Shares Change (YoY) | +160.84% |
| Shares Change (QoQ) | +24.07% |
| Owned by Insiders (%) | 20.28% |
| Owned by Institutions (%) | 4.02% |
| Float | 7.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 595.15 |
| PB Ratio | 5.77 |
| P/TBV Ratio | 5.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.62 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -317.47% and return on invested capital (ROIC) is -151.95%.
| Return on Equity (ROE) | -317.47% |
| Return on Assets (ROA) | -86.45% |
| Return on Invested Capital (ROIC) | -151.95% |
| Return on Capital Employed (ROCE) | -302.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$427,000 |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.66% in the last 52 weeks. The beta is 0.67, so BioCardia's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -39.66% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 2.01 |
| Relative Strength Index (RSI) | 56.48 |
| Average Volume (20 Days) | 78,728 |
Short Selling Information
The latest short interest is 210,690, so 1.99% of the outstanding shares have been sold short.
| Short Interest | 210,690 |
| Short Previous Month | 306,467 |
| Short % of Shares Out | 1.99% |
| Short % of Float | 2.88% |
| Short Ratio (days to cover) | 0.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | -5.25M |
| Operating Income | -8.59M |
| Pretax Income | -8.54M |
| Net Income | -8.54M |
| EBITDA | -8.55M |
| EBIT | -8.59M |
| Earnings Per Share (EPS) | -$1.66 |
Full Income StatementBalance Sheet
The company has $5.29 million in cash and $638,000 in debt, giving a net cash position of $4.65 million or $0.44 per share.
| Cash & Cash Equivalents | 5.29M |
| Total Debt | 638,000 |
| Net Cash | 4.65M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 2.63M |
| Book Value Per Share | 0.25 |
| Working Capital | 2.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.51 million and capital expenditures -$2,000, giving a free cash flow of -$7.51 million.
| Operating Cash Flow | -7.51M |
| Capital Expenditures | -2,000 |
| Free Cash Flow | -7.51M |
| FCF Per Share | -$0.71 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioCardia does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -160.84% |
| Shareholder Yield | -160.84% |
| Earnings Yield | -56.27% |
| FCF Yield | -49.51% |
Analyst Forecast
The average price target for BioCardia is $25.00, which is 1,648.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $25.00 |
| Price Target Difference | 1,648.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 247.59% |
| EPS Growth Forecast (5Y) | -39.51% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 30, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | May 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
BioCardia has an Altman Z-Score of -40.24 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.24 |
| Piotroski F-Score | 1 |
